… and outcome of patients with de novo T790M, we undertook a retrospective study to …
the treatment pattern and clinical outcomes of NSCLC patients with de novo T790 mutation. …

… TMB is negatively associated with clinical outcomes in metastatic patients with EGFR-mutant …
evaluation for T790M (using either ctDNA testing for EGFR T790M mutation, tissue PCR for …

… No T790M mutations were present in this cohort. The most common gene alteration occurred
in TP53 (10/31), followed by CDK4 (8/31), CDKN2A (7/31). Interestingly, gene alterations in …

… ] probably gives us the approach for better positioning osimertinib regarding current EGFR
TKIs in order to improve sequences with the final objective of improving patient outcomes. …

… T790M mutations … T790M mutations, when compared with L858R mutations, after resistance
to prior EGFR-TKI treatments [23]. In the present study, the incidences of T790M mutations in …

… Multivariate analysis of PPS was performed on variables selected by univariate analysis and
important clinical factors. The results of the proportional hazards model are shown in Table …

… -line treatment in the AURA3 clinical trials, patients developed drug resistance … clinical
outcome and safety of osimertinib plus anlotinib for patients with previously treated EGFR T790M…

… of T790M is associated with the benefits of clinical outcomes … T790M mutation who had
re-tested for T790M mutations in … We found that the T790M mutation could not be detected in …

… This study combines patient data from five trials in predominantly … Clinical outcomes were
analyzed to look for differences based on EGFR and KRAS genotypes, as well as clinical …

… EGFR T790M as detected by routine molecular genotyping was determined by reviewing
clinical results obtained at our institution from 2009 to 2013. We also collected outcome data …